Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising heart rhythm fix trial halted early – only 7 patients tested

NCT ID NCT03737929

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if combining surgical and catheter ablation (hybrid therapy) works better than standard catheter ablation alone for people with persistent atrial fibrillation. The trial was terminated after enrolling only 7 participants, so no meaningful conclusions can be drawn. The approach remains experimental and unproven.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hybrid ablation (surgical epicardial ablation combined with percutaneous catheter ablation)
What this could lead to
If it had succeeded, this approach could have offered a more effective treatment for persistent atrial fibrillation, potentially reducing recurrence and the need for repeat procedures.
What could go wrong
The trial was terminated early with only 7 participants, so results are not reliable. Hybrid ablation also carries higher complication risks than catheter ablation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

7 people

The number who actually took part.

Started

Jul 2019

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * To have a history of symptomatic persistent atrial fibrillation (AF) (continuous AF lasting 7 days or more) or long-standing persistent AF (continuous AF lasting for more than 12 months) * To be refractory to or intolerant to at least one class I (flecainide / propafenone) or III (sotalol / amiodarone) antiarrhythmic drug, * To be at least 18 years of age, * To agree to participate (signature of the informed consent) Exclusion Criteria: * A previous AF ablation procedure, * A longstanding persistent AF \> 3 years, * A paroxysmal AF * AF consecutive to electrolyte imbalance, thyroid disease, or other reversible non-cardiovascular cause, * Presence of left atrial appendage (LAA) thrombus, * Left atrial size ≥ 70ml/m² on transthoracic echocardiogram (TTE), * Left ventricular ejection fraction \< 35%, * Cardiac surgery (other than AF treatment) planned within 12 months, * Contra-indication to heparin and/or oral anticoagulation * Contra-indication to transoesophageal echocardiogram (TEE) * Carotid stenosis \> 80%, * Active infection or sepsis * Pleural adhesions, * Elevated hemi diaphragm * Proven and untreated sleep apnoea syndrome, * Occurrence of a cerebrovascular accident (CVA) or a transient ischemic attack (TIA) during the past 6 months, * History of blood clotting abnormalities * Indication for a permanent dual antiplatelet therapy * History of thoracic radiation, * History of myocarditis or pericarditisHistory of cardiac tamponade, * History of thoracotomy or cardiac surgery, * Body-mass-index \> 40 kg/m2, * Significant lung dysfunction * Contra-indication to anesthesia * Patient with chronic obstructive pulmonary disease (COPD) * Pregnancy, * Life expectancy less than 12 months, * Adults protected by the law

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • CHU Toulouse, Hôpital Rangueil

    Toulouse, 31059, France

  • Cardiology-rytmology

    Paris, France

  • Cardiology-rytmology service

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.